NCT03907488 · OUTCOME

Metabolic Complete Response Rate

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma · Source last updated 2026-08-04

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 4-8 weeks after last dose of study drug

What was measured

This outcome measure will be reported by 11/5/2025.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: This outcome measure will be reported by 11/5/2025.
reporting Status: NOT_POSTED
time Frame: 4-8 weeks after last dose of study drug
title: Metabolic Complete Response Rate
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice